BFC
DNLI icon

Bedel Financial Consulting’s Denali Therapeutics DNLI Stock Holding History

Bedel Financial Consulting’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-154
Closed -$7K – 986
2021
Q4 		$7K Hold
154
– – ﹤0.01% 725
2021
Q3 		$8K Hold
154
– – ﹤0.01% 701
2021
Q2 		$12K Hold
154
– – ﹤0.01% 634
2021
Q1 		$9K Hold
154
– – ﹤0.01% 654
2020
Q4 		$13K Hold
154
– – 0.01% 511
2020
Q3 		$6K Hold
154
– – ﹤0.01% 586
2020
Q2 		$4K Hold
154
– – ﹤0.01% 610
2020
Q1 		$3K Hold
154
– – ﹤0.01% 628
2019
Q4 		$3K Hold
154
– – ﹤0.01% 632
2019
Q3 		$2K Buy
+154
New +$2.94K ﹤0.01% 648

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Bedel Financial Consulting's DNLI Position: Q1 2022 in Review

Bedel Financial Consulting sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 154 shares — an estimated $7K sold.

Bedel Financial Consulting first reported a position in DNLI in Q3 2019 and held it in 10 quarters. The position peaked at $13K in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Bedel Financial Consulting reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 154 Denali Therapeutics shares in Q1 2022, an estimated $7K.
  • Bedel Financial Consulting first reported a position in Denali Therapeutics in Q3 2019 and held it in 10 quarters.
  • Bedel Financial Consulting's Denali Therapeutics position peaked at $13K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Bedel Financial Consulting's 13F filing for Q1 2022, filed 19 Apr 2022.